机构地区:[1]首都医科大学附属北京儿童医院皮肤科,北京100045 [2]昆明市儿童医院皮肤科,昆明650000 [3]河南省儿童医院皮肤科,郑州450018 [4]深圳市儿童医院皮肤科,深圳518038 [5]重庆医科大学附属儿童医院皮肤科,重庆400014 [6]上海市儿童医院皮肤科,上海200062
出 处:《中华皮肤科杂志》2023年第9期815-821,共7页Chinese Journal of Dermatology
摘 要:目的观察2%克立硼罗软膏对儿童特应性皮炎(AD)早期临床症状改善情况及不良反应耐受情况,并对比缓解期隔日给药1次(Qod)和每周给药2次(Biw)AD复发的情况。方法采用多中心、随机对照、开放标签研究,纳入首都医科大学附属北京儿童医院等6家医院2~<18岁轻中度AD患儿150例,随机分为Qod组(76例)及Biw组(74例)。在AD急性期,两组均于皮损处外用2%克立硼罗软膏及全身润肤剂,每天2次,使用2~4周,评估早期临床症状改善及不良反应发生情况。至研究者静态整体评估(ISGA)评分≤1分,进入缓解期后,两组患儿分别按Qod和Biw频率使用克立硼罗软膏维持治疗,分别评估缓解期内AD患儿复发情况,并评估缓解期第4、8、12周皮损严重程度、瘙痒、生活质量情况以及不良事件的发生情况。两组间正态分布的连续性资料比较采用t检验,非正态分布资料则采用Mann-Whitney U检验,计数资料比较采用χ^(2)检验,生存分析采用Kaplan-Meier法。结果共142例纳入改良的意向治疗分析集,其中Qod组71例,Biw组71例。在急性期,AD患儿及家属自我评估的瘙痒及皮损改善分别发生在用药1.9(1.0,3.0)d和2.0(1.0,4.1)d后。急性期治疗结束时,89例(62.7%)患儿ISGA评分达到0/1分,成功进入缓解期。83例(Qod组44例,Biw组39例)完成缓解期随访,Qod组及Biw组分别复发19例(43.2%)和12例(30.8%),两组复发率差异无统计学意义(χ^(2)=1.36,P=0.243);复发时间分别为64.2(95%CI:53.3~75.2)d和75.8(95%CI:65.5~86.1)d。在缓解期第4、8、12周未脱落的AD患儿中,仅第12周Biw组ISGA评分[0(0,1)分]显著低于Qod组[1(0,1)分,Z=-2.31,P=0.021],其余时间点两组湿疹面积及严重度指数(EASI)、ISGA、瘙痒数字评估量表(NRS)评分和生活质量评分差异均无统计学意义(均P>0.05)。共146例患儿纳入安全性数据集,研究期间65例报告70例次不良事件,发生率为44.5%,均为一般不良事件,无严重不良事件发生,55例(37.Objective To evaluate the efficacy and tolerability of crisaborole 2%ointment in the treatment of childhood atopic dermatitis(AD)at the early stage,and to compare the efficacy of every-other-day(Qod)regimen versus twice-a-week(Biw)regimen against recurrence in the remission stage of AD.Methods A multicenter,randomized,open-label clinical trial was conducted.Totally,150 children with mild to moderate AD aged 2-<18 years were enrolled from 6 hospitals(including Beijing Children′s Hospital,Capital Medical University,etc),and randomly divided into the Qod group(76 cases)and the Biw group(74 cases).In the acute stage of AD,both groups were treated with topical crisaborole 2%ointment on skin lesions twice a day for 2-4 weeks,as well as with emollients throughout the whole body.The improvement of early clinical symptoms was evaluated,and the occurrence of adverse reactions was recorded in the follow up.Once the investigator′s static global assessment(ISGA)scores decreased to 1 point or less,the patient would be enrolled into the remission stage.In the remission stage of AD,patients in the Qod group and Biw group were treated with crisaborole ointment every other day and twice a week respectively;the recurrence rate of AD in the remission stage was evaluated,as well as the severity of skin lesions,itching,life quality,and the occurrence of adverse reactions at weeks 4,8,and 12.Statistical analysis was carried out with SPSS 23.0 software by using t test for comparisons of normally distributed continuous data between two groups,Mann-Whitney U test for non-normally distributed data,chi-square test for enumeration data,and Kaplan-Meier method for analysis of survival rates.Results A total of 142 patients were enrolled in the modified intention-to-treat population,including 71 in the Qod group and 71 in the Biw group.In the acute stage of AD,the improvement of itching and skin lesions self-reported by the children or their family members occurred on days 1.9(1.0,3.0)and 2.0(1.0,4.1)after the application of crisaborole oin
关 键 词:皮炎 特应性 儿童 随机对照试验 早期 缓解期 克立硼罗
分 类 号:R758.2[医药卫生—皮肤病学与性病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...